Investments
34Portfolio Exits
10Partners & Customers
10Service Providers
3About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops, manufactures, and commercializes therapies for viral diseases, infectious diseases, and cancer utilized proprietary "combinatorial chemistry" technology to discover lead therapeutic and diagnostic compounds. Its primary areas of focus include HIV/AIDS, liver disease, and serious cardiovascular and respiratory conditions. The company was founded in 1987 and is based in Foster City, California.
Want to inform investors similar to Gilead Sciences about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Expert Collections containing Gilead Sciences
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Gilead Sciences in 2 Expert Collections, including Fortune 500 Investor list.
Fortune 500 Investor list
590 items
This is a collection of investors named in the 2019 Fortune 500 list of companies. All CB Insights profiles for active investment arms of a Fortune 500 company are included.
Diabetes
1,904 items
Latest Gilead Sciences News
May 25, 2023
May 25, 2023 Gilead Sciences, Inc. announced on May 12, 2023, that it has acquired all outstanding shares of XinThera, a San Diego-based private biotech company. The acquisition will complement Gilead's existing clinical development priorities by adding pipeline assets for well-validated targets in oncology and inflammation. The research resources of XinThera have the potential to target the DNA damage repair pathway in the treatment of cancer and to control the immune response in the treatment of inflammatory diseases, which may lead to better outcomes for patients with these diseases. Become a Subscriber According to Flavius Martin, M.D., executive vice president of research at Gilead Sciences, the XinThera team has created best-in-class small molecule drugs for the treatment of cancer and immunologic conditions. Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved medical breakthroughs for over three decades, with the aim of making the world healthier for everyone. The acquisition of XinThera is a strategic move to strengthen Gilead's early pipeline in oncology and inflammation, two areas where the company already has a strong presence. Oncology is a major area of focus for Gilead Sciences, with several oncology products already on the market. The company's current oncology portfolio includes Yescarta, a CAR T-cell therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Trodelvy, a treatment for metastatic triple-negative breast cancer; and Zydelig, a treatment for certain types of blood cancers. Inflammation is another therapeutic area where Gilead Sciences has established itself as a leader. The company's current portfolio includes filgotinib, a JAK inhibitor for the treatment of rheumatoid arthritis, and selonsertib, an investigational therapy for the treatment of liver fibrosis. The acquisition of XinThera will add to Gilead's existing pipeline in oncology and inflammation, providing the company with additional promising compounds for the treatment of these diseases. This will enable Gilead to continue to deliver on its commitment to developing breakthrough therapies for patients in need. Gilead Sciences' acquisition of XinThera is a strategic move to strengthen its early pipeline in oncology and inflammation. The addition of XinThera's pipeline assets will complement Gilead's existing clinical development priorities and provide the company with additional promising compounds for the treatment of cancer and inflammatory diseases. With a strong track record of breakthroughs in medicine, Gilead Sciences is well-positioned to continue delivering innovative therapies that make a meaningful difference in the lives of patients.
Gilead Sciences Investments
34 Investments
Gilead Sciences has made 34 investments. Their latest investment was in Ensoma as part of their Series B - II on May 5, 2023.
Gilead Sciences Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
5/16/2023 | Series B - II | Ensoma | $50M | Yes | 9 | |
5/23/2022 | Seed VC | Exavir Therapeutics | $4M | Yes | AlleyCorp, and Gilead Sciences | 1 |
5/5/2022 | Series B | Curebase | $40M | Yes | BOLD Capital Partners, GGV Capital, Gilead Sciences, Undisclosed Investors, and Xfund | 1 |
1/26/2022 | Series B | |||||
12/27/2021 | PIPE |
Date | 5/16/2023 | 5/23/2022 | 5/5/2022 | 1/26/2022 | 12/27/2021 |
|---|---|---|---|---|---|
Round | Series B - II | Seed VC | Series B | Series B | PIPE |
Company | Ensoma | Exavir Therapeutics | Curebase | ||
Amount | $50M | $4M | $40M | ||
New? | Yes | Yes | Yes | ||
Co-Investors | AlleyCorp, and Gilead Sciences | BOLD Capital Partners, GGV Capital, Gilead Sciences, Undisclosed Investors, and Xfund | |||
Sources | 9 | 1 | 1 |
Gilead Sciences Portfolio Exits
10 Portfolio Exits
Gilead Sciences has 10 portfolio exits. Their latest portfolio exit was Tmunity on December 20, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
12/20/2022 | Acquired | 17 | |||
4/30/2021 | IPO | Public | 9 | ||
4/14/2021 | Acq - Pending | 2 | |||
Date | 12/20/2022 | 4/30/2021 | 4/14/2021 | ||
|---|---|---|---|---|---|
Exit | Acquired | IPO | Acq - Pending | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 17 | 9 | 2 |
Gilead Sciences Acquisitions
24 Acquisitions
Gilead Sciences acquired 24 companies. Their latest acquisition was XinThera on May 09, 2023.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
5/9/2023 | Series B | $80M | Acquired | 1 | ||
8/4/2022 | Series B | $130.28M | Acquired | 8 | ||
12/10/2020 | Series B | $10.71M | Acquired | 6 | ||
10/23/2020 | Other Venture Capital | |||||
3/2/2020 | Grant |
Date | 5/9/2023 | 8/4/2022 | 12/10/2020 | 10/23/2020 | 3/2/2020 |
|---|---|---|---|---|---|
Investment Stage | Series B | Series B | Series B | Other Venture Capital | Grant |
Companies | |||||
Valuation | |||||
Total Funding | $80M | $130.28M | $10.71M | ||
Note | Acquired | Acquired | Acquired | ||
Sources | 1 | 8 | 6 |
Gilead Sciences Partners & Customers
10 Partners and customers
Gilead Sciences has 10 strategic partners and customers. Gilead Sciences recently partnered with Roche on May 5, 2023.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
5/11/2023 | Licensee | Switzerland | HOOKIPA Pharma Reports First Quarter 2023 Financial Results and Recent Business Highlights The primary drivers of the increase in research and development expenses by $ 4.3 million compared to the three months ended March 31 , 2022 were higher clinical study expenses for our HB-200 program and higher expenses for research and development services for our HB-200 program , as well as increased spending for our Gilead and Roche partnered programs , partially offset by lower manufacturing expenses for our HB-200 and Gilead partnered programs . | 2 | |
5/9/2023 | Licensor | United States | NEW YORK and VIENNA , Austria , May 09 , 2023 -- HOOKIPA Pharma Inc. , a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform , today announced that the first person has been dosed in a Gilead-led Phase 1 clinical trial of HB-400 , an investigational therapeutic vaccine for chronic hepatitis B. HB-400 is one of two novel compounds being developed in collaboration with Gilead . | 2 | |
2/2/2023 | Partner | United States | Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results The increase was primarily driven by two charges in the fourth quarter of 2021 which did not recur in 2022 : the $ 1.25 billion charge for a legal settlement and the $ 625 million charge for the Arcus Biosciences , Inc. collaboration opt-in . | 2 | |
1/31/2023 | Partner | ||||
1/30/2023 | Partner |
Date | 5/11/2023 | 5/9/2023 | 2/2/2023 | 1/31/2023 | 1/30/2023 |
|---|---|---|---|---|---|
Type | Licensee | Licensor | Partner | Partner | Partner |
Business Partner | |||||
Country | Switzerland | United States | United States | ||
News Snippet | HOOKIPA Pharma Reports First Quarter 2023 Financial Results and Recent Business Highlights The primary drivers of the increase in research and development expenses by $ 4.3 million compared to the three months ended March 31 , 2022 were higher clinical study expenses for our HB-200 program and higher expenses for research and development services for our HB-200 program , as well as increased spending for our Gilead and Roche partnered programs , partially offset by lower manufacturing expenses for our HB-200 and Gilead partnered programs . | NEW YORK and VIENNA , Austria , May 09 , 2023 -- HOOKIPA Pharma Inc. , a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform , today announced that the first person has been dosed in a Gilead-led Phase 1 clinical trial of HB-400 , an investigational therapeutic vaccine for chronic hepatitis B. HB-400 is one of two novel compounds being developed in collaboration with Gilead . | Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results The increase was primarily driven by two charges in the fourth quarter of 2021 which did not recur in 2022 : the $ 1.25 billion charge for a legal settlement and the $ 625 million charge for the Arcus Biosciences , Inc. collaboration opt-in . | ||
Sources | 2 | 2 | 2 |
Gilead Sciences Service Providers
7 Service Providers
Gilead Sciences has 7 service provider relationships
Service Provider | Associated Rounds | Provider Type | Service Type |
|---|---|---|---|
Acq - P2P, and Acquired | Investment Bank | Financial Advisor | |
Service Provider | |||
|---|---|---|---|
Associated Rounds | Acq - P2P, and Acquired | ||
Provider Type | Investment Bank | ||
Service Type | Financial Advisor |
Partnership data by VentureSource
Gilead Sciences Team
35 Team Members
Gilead Sciences has 35 team members, including current Chief Executive Officer, Michael Riordan.
Name | Work History | Title | Status |
|---|---|---|---|
Michael Riordan | Chief Executive Officer | Current | |
Name | Michael Riordan | ||||
|---|---|---|---|---|---|
Work History | |||||
Title | Chief Executive Officer | ||||
Status | Current |
Compare Gilead Sciences to Competitors
AbbVie (NYSE: ABBV) researches and develops pharmaceutical products. The company produces pharmaceutical drugs for specialty therapeutic areas such as immunology, chronic kidney disease, hepatitis C, women's health, oncology, and neuroscience. It also offers treatments for diseases including multiple sclerosis, Parkinson's, and Alzheimer's disease. The company was founded in 2013 and is based in North Chicago, Illinois.
Capital Rx is a healthcare technology company. It offers a pharmacy benefits management (PBM) platform that reduces administrative costs, improves patient outcomes, and delivers a superior customer experience. It also offers prescription savings cards. It was founded in 2017 and is based in New York, New York.
H&S Tech is a manufacturer and distributor of disposable packaging and medical products from South Korea and China. It supplies general to custom products for government sectors, retail sectors, and food distribution sectors. The company delivers within the United States. It was founded in 2019 and is based in Anaheim, California.
Cardinal Health manufactures and distributes medical and laboratory products and is a provider of performance and data solutions for healthcare facilities. It helps pharmacies, hospitals, and ambulatory care sites focus on patient care while reducing costs, improving efficiency and quality, and increasing profitability. Cardinal Health is a link in the healthcare supply chain, providing products from suppliers to medical professionals and healthcare facilities. The company was founded in 1979 and is based in Dublin, Ohio.
Theracell Advanced Biotechnology provides personalized and precision medicine, enabling individualized treatment with improved outcome. It offers advanced therapy medicinal products (ATMP), which are comprised of gene therapy, somatic cell therapy, and tissue engineered products. Based on viable cells or tissues, their pharmacological, immunologic or metabolic action should be considered as the principal mode of action. The company's therapeutic portfolio spans the areas of orthopedics, dermatology, nephrology, immuno-oncology, and tissue repair and regeneration. Through strategic partnerships Theracell Advanced Biotechnology participates in the global vision of the realization of personalized medicine tailored to individual patient needs.
McKesson (NYSE: MCK) is a healthcare services and information technology company that focuses on improving health outcomes for patients. It serves hospitals, physician offices, pharmacies, and pharmaceutical companies. The company was founded in 1833 and is based in Irving, Texas.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.